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ABSTRACT
Objective To report on the demographic data from the 
fi rst 18 months of enrollment to an international registry 
on autoinfl ammatory diseases in the context of the 
Eurofever project.
Methods A web-based registry collecting baseline and 
clinical information on autoinfl ammatory diseases and 
related conditions is available in the member area of the 
PRINTO web-site. Anonymised data were collected with 
standardised forms.
Results 1880 (M:F=916:964) individuals from 67 
centers in 31 countries have been entered in the 
EUROFEVER registry. Most of the patients (1388; 74%), 
reside in western Europe, 294 (16%) in the eastern and 
southern Mediterranean region (Turkey, Israel, North 
Africa), 106 (6%) in eastern Europe, 54 in Asia, 27 in 
South America and 11 in Australia. In total 1049 patients 
with a clinical diagnosis of a monogenic autoinfl ammatory 
diseases have been enrolled; genetic analysis was 
performed in 993 patients (95%): 703 patients have 
genetically confi rmed disease and 197 patients are 
heterozygous carriers of mutations in genes that 
are mutated in patients with recessively inherited 
autoinfl ammatory diseases. The median diagnosis delay 
was 7.3 years (range 0.3–76), with a clear reduction 
in patients born after the identifi cation of the fi rst gene 
associated with autoinfl ammatory diseases in 1997.
Conclusions A shared online registry for patients with 
autoinfl ammatory diseases is available and enrollment is 
ongoing. Currently, there are data available for analysis 
on clinical presentation, disease course, and response 
to treatment, and to perform large scale comparative 
studies between different conditions.
INTRODUCTION
The autoinfl ammatory diseases are a group of 
infl ammatory conditions associated with abnormal 
regulation of innate immunity.1 The fi rst molecular 
genetic characterisation of an autoinfl ammatory dis-
ease was in 1997, when two consortia independently 
identifi ed the association between mutations of the 
MEFV (MEditerranean FeVer) gene and Familial 
Mediterranean fever (FMF).2 3 Over the last decade, 
a number of monogenic and multifactorial diseases 
have been identifi ed or reclassifi ed as autoinfl amma-
tory in aetiology1 4. With the sole exception of FMF, 
which is highly prevalent in some ethnicities (Turks, 
Arabs, non-Ashkenazi Jews and Armenians)5, the 
incidence of autoinfl ammatory diseases is low, rang-
ing from estimated population frequencies of 1 to 
3 per million for the cryopyrin associated periodic 
syndromes (CAPS)6 to less than 10 reported fami-
lies for the most rare conditions, such as defi ciency 
of IL-1 receptor antagonist (DIRA) or familial cold 
autoinfl ammatory syndrome 2 (FCAS2) associated 
with NLRP12 gene mutations.7 8
Our knowledge of autoinfl ammatory diseases, 
although expanding rapidly, is still very limited. 
Genotype-phenotype correlations and the potential 
infl uences of environmental and epigenetic factors 
are still largely unknown and, with the exception 
of CAPS and DIRA, their molecular pathogenesis 
remains elusive. Clinically, the rarity and pheno-
typic variability of most of these diseases means 
that delayed diagnosis is the norm. Even once a 
diagnosis has been reached we still struggle to pro-
vide patients and parents with defi nitive answers 
as to the best treatments available and their long 
term prognosis.
A major limitation to understanding these rare 
conditions has been the fragmentation of clinical 
experience with very few centers in any country 
caring for more than a handful of cases. In order 
to counteract this an international study, named 
EUROFEVER has been supported by the Executive 
Agency for Health and Consumers of European 
Union (EAHC, Project No2007332)9. The general 
aims of the project are: (i) to promote awareness 
and enhance early recognition of these diseases 
among the medical community; (ii) to provide 
clear and comprehensive information to families 
and patients affected by these conditions, (iii) to 
improve knowledge of the clinical presentation, 
response to treatment and long term complica-
tions of these disorders. The major practical part 
of the project was to set up an international web-
based registry of autoinfl ammatory diseases. In 
this article we report on the demographic data of 
the patients enrolled during the fi rst 18 months of 
the EUROFEVER registry.
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METHODS
A common registry for autoinfl ammatory diseases
The monogenic autoinfl ammatory diseases included were: FMF, 
CAPS, tumor necrosis factor -receptor associated periodic syn-
drome (TRAPS), Mevalonate kinase defi ciency (MKD), Blau syn-
drome, Pyogenic Sterile Arthritis, Pyoderma Gangrenosum and 
Acne (PAPA) syndrome, DIRA and FCAS2. Other multifactorial 
autoinfl ammatory syndromes, such as chronic recurrent mul-
tifocal osteomyelitis (CRMO), Behcet’s disease, periodic fever, 
aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) 
and patients with undefi ned periodic fevers were included.
Experts in autoinfl ammatory diseases and syndromes were 
initially asked to identify the variables they considered of inter-
est for each disease. A draft data collection form was then sent 
to all the experts for their review. Five main categories were con-
sidered: (i) baseline information, (ii) clinical manifestations, (iii) 
laboratory examinations, (iv) imaging and other diagnostic pro-
cedures and (v) response to treatments. Further revisions of the 
forms were subsequently evaluated by the experts with a fi nal 
approval of the defi nitive version by nominal group technique10 
during a Consensus Meeting in March 2009.
The baseline data included: age, gender, country of birth and of 
residence, ethnicity, age at disease onset and at diagnosis and date 
of fi rst and last visits to the treating center. Genetic testing was not 
mandatory for inclusion. Where performed, details on the genetic 
analysis were sought: gene screened, extent of the analysis (spe-
cifi c mutations, selected exons, complete gene sequencing), muta-
tions detected (a list was continuously updated from the Infever 
database, http://fmf.igh.cnrs.fr/ISSAID/infevers/)11, and laboratory 
where the analyses were performed. Finally, information on con-
sanguinity and any relevant family history was collected. Patient 
data was anonymised and cases identifi ed by alphanumeric codes.
Table 1 Demographic characteristics of patients enrolled in the registry in the fi rst 18 months
Disease Patient number M/F
Age at enrollment in 
years. Median (range)
Children*/adults 
at enrollment Western Europe Eastern Europe
Eastern – southern 
Mediterrean Others
FMF 554 268/286 11 (1–86) 456/98 297 4 214 39
TRAPS 199 101/98 23 (2–77) 85/114 192 4 2 1
CAPS 152 79/73 15 (0–77) 91/61 131 4 3 14
MKD 104 47/57 14 (1–60) 65/39 94 4 1 5
Blau 25 13/12 13 (3–51) 18/7 15 0 0 10
PAPA 7 3/4 18 (4–30) 3/4 6 1 0 0
FCAS2 6 5/1 50 (13–79) 2/4 4 0 0 2
DIRA 2 0/2  5 (1–9) 2/0 2 0 0 0
CRMO 245 88/157 14 (1–61) 204/41 228 4 0 13
PFAPA 361 208/153  6 (0–37) 352/9 221 66 69 5
Behçet 65 27/38 15 (5–25) 47/18 52 7 4 2
Undefi ned PF 160 77/83 14 (2–71) 99/61 146 12 1 1
*age <18 years.
CAPS, diseases from the spectrum of cryopyrin associated periodic fever syndromes; CRMO, chronic recurrent multifocal osteomyelitis; DIRA, defi ciency of the interleukin-1-receptor 
antagonist; F, female; FCAS2, familial cold autoinfl ammatory syndrome 2; FMF, familial Mediterranean fever; M, male; MKD, mevalonate-kinase defi ciency; PAPA, pyogenic sterile 
arthritis, pyoderma gangrenosum and acne syndrome; PF, periodic fever; PFAPA, periodic fever syndrome with aphthous stomatitis, pharyngitis and cervical adenopathy; TRAPS, 
tumour necrosis factor receptor associated periodic syndrome.
Figure 1 Distribution of patients according to the country of residency in Europe and the Mediterranean region. Other patients living in Saudi Arabia 
(33), Argentina (23), Australia (11), India (5), Oman (4), Kuwait (3), Guadalupe (2), Uruguay (1) and Martinique (1) are also reported.
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Dissemination and data collection
The Eurofever project survey involved all centers linked to 
the Pediatric Rheumatology INternational Trial Organisation 
(PRINTO), a non-profi t organisation devoted collaborative stud-
ies, that now encompass more than 400 centers in 60 countries 
worldwide12 and asked about their experience in autoinfl amma-
tory diseases. The survey results are available on the Eurofever 
website (www.printo.it/eurofever).
In addition, centers involved in the diagnosis and manage-
ment of autoinfl ammatory diseases in adults were contacted 
and information on the study and how to participate was dis-
seminated to members of the International Society of Systemic 
Autoinfl ammatory Diseases, the European League Against 
Rheumatism, the European Society of Immune-Defi ciencies 
(ESID), through personal contacts, lectures and scientifi c com-
munications and links to the Eurofever website.
The database has been developed with a sql server with 
through access via the member area of the PRINTO website 
(www.printo.it) with username and password on an https plat-
form and URL parameters crypted. Only centers authorised (eg, 
centers with ethics committee approval) by the PRINTO coor-
dinating were allowed to access the online database. Inclusion 
criteria for each disease were approved during the consensus 
conference and are reported in supplemental material. Ethical 
committee approval for entering patients in the registry was 
obtained in the participating centers as required by local legal 
requirements.12 Informed consent/assent as appropriate by the 
national laws in each country was signed by parents or legal 
representatives or child of adequate age. Enrollment started on 
November 2009.
Statistical tests were performed using subroutines from the 
statistical analysis package by MS Excel version 11.0.
RESULTS
General demographic data
By data lock in July 2011, 1880 patients (M:F=916:964) from 67 
centers in 31 countries have been entered in the registry, 30 cen-
ters (45%) required ethical committee approval. Enrolling coun-
tries, in alphabetic order, were: Albania, Argentina, Australia, 
Belgium, Croatia, Czech Republic, Denmark, France, Georgia, 
Germany, Greece, Hungary, India, Israel, Italy, Latvia, Lithuania, 
Netherlands, Oman, Poland, Romania, Russia, Saudi Arabia, 
Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey 
and the UK.
The same Centres enrolled also patients living in other 
countries (Algeria, Cyprus, Egypt, Guadalupe, Iceland, Ireland, 
Kuwait, Lebanon, Martinique, Morocco, Norway, Uruguay, 
Tunisia). The distribution of the patients by country of residence 
is shown in fi gure 1. Most of the enrolled patients (1388; 74%) 
were resident in western Europe, 294 patients (16%) in the east-
ern and southern Mediterranean (Turkey, Israel, north Africa), 
106 (6%) in eastern Europe (Croatia, Czech Republic, Hungary, 
Latvia, Lithuania, Poland, Romania, Russia, Serbia, Slovakia, 
Slovenia), 54 in Asia, 27 in South America and 11 in Australia. 
The number of enrolled patients for each disease and their dis-
tribution according to the region of residence are shown in table 
1. At the time of enrollment, 1424 patients (76%) were children 
and 456 (24%) were adults.
Monogenic autoinfl ammatory diseases
In total, 1049 patients were enrolled with a diagnosis of a 
monogenic autoinfl ammatory disease; 703 had genetic results 
completely consistent with the diagnosis; 197 had a heterozy-
gous mutation in a classically autosomal recessive disease; 93 
had no mutations detected and 56 patients had not been geneti-
cally tested. Most of these latter patients were not resident in 
western Europe and testing was not performed for technical or 
fi nancial reasons. The distribution of these patients is shown in 
fi gure 2. Conceivably, the rather high rate of genetically con-
fi rmed patients was due to the selective recruitment of these 
patients by the centers.
There was a marked delay between disease onset and diag-
nosis for all diseases – with a median of 7.3 years (fi gure 3A). 
Encouragingly there was a trend towards shorter diagnostic 
delay in patients born more recently (fi gure 3B). This was more 
obvious for diseases described over the last 3 or 4 decades, such 
as MKD, TRAPS and the more severe variant of CAPS known 
as CINCA/NOMID, especially after the respective molecu-
lar defects were identifi ed.13–15 Nonetheless even in patients 
born in the 21st century the median diagnostic delay remained 
Figure 2 Distribution of patients with autoinfl ammatory diseases according to disease diagnosis and genetic confi rmation. FMF, familial 
Mediterranean fever; MKD, mevalonate-kinase defi ciency; TRAPS, tumour necrosis factor receptor associated periodic syndrome; CAPS, cryopyrin 
associated periodic syndromes; PAPA, pyogenic sterile arthritis, pyoderma gangrenosum and acne syndrome; DIRA, defi ciency of the interleukin-1-
receptor antagonist; FCAS2, familial cold autoinfl ammatory syndrome 2; PFAPA, periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis 
syndrome; CRMO, chronic recurrent multifocal osteomyelitis. MEFV, MEditerrean FeVer; TNFRSF1A, Tumour necrosis factor receptor superfamily 
member 1A; NOD2, nucleotide-binding oligomerisation domain-containing protein 2; NLRP3, NOD-like receptor 3; MVK, mevalonate-kinase; SNPs, 
single nucleotide polymorphisms.
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relatively long: 1.4 years (range 0.2–9) for FMF, 1.2 years (0.1–7.4) 
for TRAPS, 1.4 years (0.2–8.9) for CAPS and 2.5 years (0.1–8.3) 
for MKD.
At the time of the enrollment the majority of patients (85%) 
were still followed by the referral centers; 638/723 (89%) chil-
dren (age < 18 years) and 254/326 (78%) adults.
The distribution of the 554 FMF patients (456 children and 
98 adults) according to their ethnicity and region of residence is 
given in table 2. Mutations found in FMF patients are reported 
in supplementary table I. Consanguinity was present in 78 fami-
lies, and 187 patients (34%) declared a positive family history.
Among the 199 TRAPS patients (85 children, 114 adults) 
there were 45 separate mutations, 3 of which were previously 
unreported (supplementary table I). Eighty-four (42%) patients 
reported a family history of disease; most of these carried a 
cysteine or the p.T50M mutation. The low-penetrance p.R92Q 
and p.P46L variants were reported in 75 and 7 patients, respec-
tively (supplementary table I). The careful analysis of the clinical 
manifestations of this latter group of patients will help in the 
characterisation of the actual impact of this variant on the phe-
notype in comparison with mutations of the TNFRSF1A gene.16
One hundred fi fty-two patients (91 children and 61 adults) 
with CAPS were enrolled in the registry. Among 30 NLRP3 
mutations detected, 2 were previously unreported (supplemen-
tary table I). A positive family history was present in 73 (48%) 
patients.
There were 104 MKD patients (65 children, 39 adults) with 29 
MVK variants, 4 of which were previously unreported (supple-
mentary table I). Eight families were consanguineous and there 
was a positive family history in 27 (26%) patients.
Among the 25 Blau syndrome patients 8 had genetic confi rma-
tion. Following mutations were reported: p.R334Q,2 p.R334W,2 
p.R587C.2 A new mutation, p.E600K, was found in 2 patients. 
Three polymorphisms were also found: p.P268S/SNP5 (fi ve 
patients), p.R587R/SNP7 (one patient), p.R702W/SNP8 (one 
patient).
Six of seven patients with PAPA syndrome had confi rmed 
mutations there were 3 previously described PSPTTP1 variants 
(p.A230T, p.E250K and p.E250Q) and 3 novel variants (p.V344I, 
p.E256G, p.G904A) non already reported in Infevers.
There were six patients with the FCAS2 associated to 
NLRP12 mutations; a pair of twins from Guadalupe displayed 
the p.R284X mutation and four Italian patients displayed the 
p.D294E mutation.
Finally, two patients with DIRA were enrolled from the 
Netherlands and were homozygous for the E77X mutation of 
the IL1RN gene.
Multifactorial conditions without clear genetic aetiology and 
undefi ned periodic fevers
Two hundred forty-fi ve patients (204 children and 41 adults) 
with CRMO were enrolled in the registry. The oldest patient 
was a 61-years-old man who was diagnosed in 2010. Six fami-
lies were consanguineous and there was a positive family his-
tory in fi ve patients.
Sixty-fi ve patients with Behçet disease (47 children and 18 
adults) were in the registry. Three families were consanguineous 
and there was a positive family history in 14 patients.
Three hundred sixty-one PFAPA patients were entered in 
the registry. Although nine of them were adults, the majority 
of patients (88%) were less than 5-years-old at disease onset, 
eight patients presented after the age of 10. Five families were 
consanguineous and 36 other patients (10%) presented with a 
family history of PFAPA. One hundred sixty patients (99 chil-
dren and 61 adults) were enrolled in the category of undefi ned 
periodic fever. In the majority (115, 72%), the disease onset 
was in childhood. Twenty-four patients (15%) presented after 
the age of 30. Three families are consanguineous and a positive 
family history was reported in 14 sporadic cases. One hundred 
sixteen patients (72%) were screened for at least one autoin-
fl ammatory diseases-associated gene. No mutations were found 
in 83%. Notably, despite the presence of low-penetrance vari-
ants, 20 patients were included this subgroup as the entering 
centers felt that their clinical manifestations were not consis-
tent with disease normally associated with that gene. The vari-
ous mutations found were the p.R92Q variant of TNFRSF1A 
Figure 3 Diagnostic delay in patients with monogenic autoinfl ammatory diseases. The difference between the age at disease onset (white bars) 
and diagnosis (grey bars) is shown in panel A. Boxes contain values falling between the 25th and 75th percentiles, lines represent median values, 
whiskers lines that extend from the boxes represent the highest and lowest non-outlier values for each subgroups. Panel B: variation of diagnostic 
delay according to the decade of birth in four main inherited autoinfl ammatory diseases (FMF, familial Mediterranean fever; MKD, mevalonate-kinase 
defi ciency; TRAPS, tumour necrosis factor receptor associated periodic syndrome CAPS, cryopyrin associated periodic syndrome). The number 
of patients are reported for each disease. For the fi rst decade of the XXI century data on 265 FMF, 43 CAPS, 41 TRAPS and 35 MKD patients are 
available.
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(six patients); MEFV mutations in nine patients (p.R202Q,4 
p.E148Q,2 p.A744S,1 p.S309F1 and p.V726A),1 the p.T356M 
mutation of MVK (two patients), and the p.V198M,1 p. Q703K1 
and p.T219T1 variants of NLRP3.
DISCUSSION
To be successful, a rare disease registry needs to be genuinely 
international and requires active ongoing support by centers 
involved in diagnosing and managing the patients. PRINTO, 
which has a track record of establishing a successful network 
of centers in Pediatric Rheumatology, provided a starting point 
for this brand new initiative in the autoinfl ammatory diseases. 
Although this EU- funded project was particularly directed at 
Europe the pre-existing PRINTO network facilitated expansion 
to other geographic areas. The broad coverage of pediatric centers 
was crucial because, as shown by the present study, the major-
ity of patients with autoinfl ammatory diseases have an early 
disease onset.17 Autoinfl ammatory diseases are also diagnosed 
by adult specialists (rheumatologists, clinical immunologists and 
geneticists, experts in amyloidosis) and other pediatric subspe-
cialists (immunologists, neonatologists, experts in infectious dis-
eases). A major effort of the project was to expand the network 
as widely as possible by actively inviting pediatric and adult cen-
ters known to have an interest in the diagnosis and management 
of these patients. This was made simpler by the involvement 
of initiatives such as EUROTRAPS (http://fmf.igh.cnrs.fr/ISSAID/
EUROTRAPS/) and Hyper IgD registry (http://hids.net) and 
international scientifi c societies. The ability to integrate with 
pre-existing registries and resources such as Infevers11 shows 
the power of web-based initiatives in collecting, collating and 
distributing data in rare diseases and in promoting networks of 
interested centres which can provide mutual support in diagno-
sis and management. Plans for further collaborations with other 
international and national initiatives are ongoing.18 Although a 
number of important geographic areas (North America, many 
south American and Asian countries) are not yet covered by 
the registry, the large number of patients recruited in this fi rst 
period of the project and the wide geographical distribution is 
very encouraging and suggests that the network can continue to 
grow and prove an invaluable long term resource in the study of 
autoinfl ammatory diseases.
One of the most pressing issues in the rare diseases is delayed 
diagnosis. Autoinfl ammatory attacks are extremely unpleas-
ant and frequently preventable with current treatments and 
untreated disease carries a risk of increased morbidity and irre-
versible long term damage. The dramatic decrease in diagnostic 
delay in the last decade is, to some extent, simply due to the fact 
that many of these diseases are recently recognised clinical enti-
ties and that genetic diagnosis has only become relatively widely 
available in the last few years. The fi rst gene to be identifi ed 
in autoinfl ammatory diseases was MEFV in 19972 3 and with 
identifi cation of ILR1N in 20097 the number of genetically char-
acterised autoinfl ammatory diseases reached eight. Nonetheless 
the diagnosis of autoinfl ammatory diseases relies on a clinical 
suspicion and many cases are missed due to poor recognition of 
these exceptionally rare. The uneven geographic distribution of 
cases reported here with a marked bias towards western Europe, 
where there are a relatively large number of specialist centers 
with facilities for genetic analysis, highlights this problem and 
supports the results of a survey performed among PRINTO 
and ESID centers which suggested that poor recognition of the 
autoinfl ammatory diseases is even more marked in the eastern 
European countries.19
The main aim of our project was to set-up a long term regis-
try for the very rare monogenic diseases (TRAPS, CAPS, MKD, 
Blau disease, NLRP12-associated disease, DIRA, PAPA syn-
drome). FMF has a high prevalence in some ethnicities and a 
previous multi-national collaboration (Meta-FMF) has collected 
a large case series.20 The aim of Eurofever in FMF was not to 
set up a formal registry of all existing FMF patients, but rather 
to collect information on unselected cohorts of FMF patients 
of different ethnicities and residing in different regions with 
a view to compare them with the other monogenic periodic 
syndromes. A cohort of patients with multifactorial diseases 
which enter the differential diagnosis, such as PFAPA syn-
drome, CRMO and Behçet disease, were also enrolled with a 
view to comparative studies.
Detailed data on clinical manifestations and response to treat-
ment are already available for more than 70% of patients. For 
each completed patient, an internal validation process is provided 
by the participating experts. The aim of this validation process 
is to select patients with an unequivocal genetic and/or clinical 
picture for future studies on genotype-phenotype correlations, 
complication and response to treatment. Moreover, appropriate 
genetic testing will be offered to patients with a strong clinical 
suspicion for a given disease that has not been analysed so far. 
The registry is still actively recruiting and new patients will be 
included in the follow-up of the project that will continue in the 
long term. Moreover, newly recognised monogenic autoinfl am-
matory diseases will be also included.21–23
Establishment of a large cohort and prolonged follow-up 
data will allow statistically robust and clinically meaningful 
analysis of phenotype/genotype correlations, complications 
and response to treatment for most of the disease involved. 
Standardised collection of clinical data on both rare monogenic 
autoinfl ammatory diseases and more frequent conditions will 
facilitate comparison of different diseases. This will overcome 
the problems inherent in single disease registries when generat-
ing evidence-based diagnostic and classifi cation criteria and/or 
indications for the molecular analysis24 25.






Europe Turks in Turkey Jews in Israel
Arabs†/Jews/
Turks in WE* Arabs‡ Other
Genetically confi rmed 304 (55) 146/158 249/55 80 118 22 19/6/16 24 19
Heterozygous 172 (31)  81/91 148/24 92 25 15 15/3/4 9 9
Clinically suspected 78 (14)  41/37  59/19 32 1 14  4/1/4 14 8
All 554 268/286 456/98 204 144 51 38/10/24 47 36
*resident in western Europe.
†including north Africans.
‡including north Africans and Arabs living in north Africa and in Arabian countries.
F, female; M, male; WE, Western Europe.
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Approximately 75–80% of patients with clinical features 
consistent with autoinfl ammatory diseases have no recognised 
mutations in any of the known genes.24 26–28 A large cohort of 
patients with undefi ned periodic fevers will allow characterisa-
tion of novel genes in this currently challenging disease group. 
For each patient of this particular subgroup a panel of experts 
will evaluate the possible indications for the implementation 
of molecular screening for already known genes. In any case, 
the identifi cation of ‘genetically negative’ patients with a well 
characterised clinical phenotype (ie, CAPS-like patients) and the 
cohort of individuals and families with an undefi ned periodic 
fever syndrome are a future resource for linkage and/or next 
generation sequencing analyses.29 30
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